Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Viracta Therapeutics (Nasdaq: VIRX), a clinical-stage precision oncology company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, at 8:30 a.m. EDT in New York City. Mark Rothera, President and CEO of Viracta, will be presenting at the conference.

Viracta focuses on developing treatments for virus-associated cancers that affect patients worldwide. Investors and interested parties can access a live webcast of the presentation through the company's website under the 'Events and Presentations' section. The webcast will remain archived for 90 days following the event, allowing for later viewing.

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, will present at the H.C. Wainwright 26^th Annual Global Investment Conference taking place in New York City on Wednesday, September 11, 2024, at 8:30 a.m. EDT.

A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Presentations" and archived for 90 days.

About Viracta Therapeutics, Inc.
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a potentially registrational, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV⁺ nasopharyngeal carcinoma (NPC) and other advanced EBV⁺ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

For additional information, please visit www.viracta.com.

Investor Relations Contact:
Michael Faerm
Chief Financial Officer
Viracta Therapeutics, Inc.
ir@viracta.com

SOURCE Viracta Therapeutics, Inc.

FAQ

When and where will Viracta Therapeutics (VIRX) present at the H.C. Wainwright Global Investment Conference?

Viracta Therapeutics (VIRX) will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 8:30 a.m. EDT in New York City.

Who will be presenting for Viracta Therapeutics (VIRX) at the investment conference?

Mark Rothera, President and Chief Executive Officer of Viracta Therapeutics (VIRX), will be presenting at the H.C. Wainwright Global Investment Conference.

How can investors access Viracta Therapeutics' (VIRX) presentation at the conference?

Investors can access a live webcast of Viracta Therapeutics' (VIRX) presentation on the Investors section of the company's website under 'Events and Presentations'.

How long will Viracta Therapeutics' (VIRX) presentation be available for viewing after the conference?

Viracta Therapeutics' (VIRX) presentation will be archived on their website for 90 days following the H.C. Wainwright Global Investment Conference.

What is the main focus of Viracta Therapeutics (VIRX) as a company?

Viracta Therapeutics (VIRX) is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.